These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 22275828)

  • 1. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.
    Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS
    Int J Nanomedicine; 2012; 7():123-31. PubMed ID: 22275828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye.
    Natarajan JV; Chattopadhyay S; Ang M; Darwitan A; Foo S; Zhen M; Koo M; Wong TT; Venkatraman SS
    PLoS One; 2011; 6(9):e24513. PubMed ID: 21931735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits.
    Fahmy HM; Saad EAES; Sabra NM; El-Gohary AA; Mohamed FF; Gaber MH
    Int J Pharm; 2018 Sep; 548(1):597-608. PubMed ID: 29997042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodegradable nanoparticles for controlled subconjunctival delivery of latanoprost acid: in vitro and in vivo evaluation. Preliminary results.
    Giarmoukakis A; Labiris G; Sideroudi H; Tsimali Z; Koutsospyrou N; Avgoustakis K; Kozobolis V
    Exp Eye Res; 2013 Jul; 112():29-36. PubMed ID: 23603320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety assessment of subconjunctivally implanted devices containing latanoprost in Dutch-belted rabbits.
    Jessen BA; Shiue MH; Kaur H; Miller P; Leedle R; Guo H; Evans M
    J Ocul Pharmacol Ther; 2013; 29(6):574-85. PubMed ID: 23489175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys.
    Ciolino JB; Ross AE; Tulsan R; Watts AC; Wang RF; Zurakowski D; Serle JB; Kohane DS
    Ophthalmology; 2016 Oct; 123(10):2085-92. PubMed ID: 27586444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma.
    Kashiwagi K; Ito K; Haniuda H; Ohtsubo S; Takeoka S
    Invest Ophthalmol Vis Sci; 2013 Aug; 54(8):5629-37. PubMed ID: 23868986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents.
    Brugnera M; Vicario-de-la-Torre M; González-Cela Casamayor MA; López-Cano JJ; Bravo-Osuna I; Huete-Toral F; González Rubio ML; Carracedo G; Molina-Martínez IT; Andrés-Guerrero V; Herrero-Vanrell R
    Drug Deliv Transl Res; 2024 Oct; 14(10):2804-2822. PubMed ID: 38602615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous Beagle.
    Gelatt KN; MacKay EO
    Vet Ophthalmol; 2001 Dec; 4(4):283-8. PubMed ID: 11906665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
    Wang RF; Gagliuso DJ; Mittag TW; Podos SM
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
    Diestelhorst M
    Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of latanoprost when stored at room temperature.
    Mochizuki H; Itakura H; Takamatsu M; Kiuchi Y
    Hiroshima J Med Sci; 2008 Jun; 57(2):69-72. PubMed ID: 18717189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension.
    Cheng YH; Hung KH; Tsai TH; Lee CJ; Ku RY; Chiu AW; Chiou SH; Liu CJ
    Acta Biomater; 2014 Oct; 10(10):4360-6. PubMed ID: 24914827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two- and three-times-daily topical ophthalmic application of 0.005% latanoprost solution in clinically normal dogs.
    Tofflemire KL; Whitley EM; Allbaugh RA; Ben-Shlomo G; Robinson CC; Overton TL; Thiessen CE; Evans EA; Griggs AN; Adelman SA; Ludwig AL; Jens JK; Ellinwood NM; Peterson CS; Whitley RD
    Am J Vet Res; 2015 Jul; 76(7):625-31. PubMed ID: 26111092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma.
    Sponsel WE; Paris G; Trigo Y; Pena M
    Am J Ophthalmol; 2002 Oct; 134(4):552-9. PubMed ID: 12383812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.